SIC
NBIX icon

SJS Investment Consulting’s Neurocrine Biosciences NBIX Stock Holding History

SJS Investment Consulting’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43K Sell
255
-86
-25% -$12.8K ﹤0.01% 520
2026
Q1 		$44.9K Buy
341
+137
+67% +$18.2K 0.01% 433
2025
Q4 		$28.9K Buy
204
+197
+2,814% +$28.5K ﹤0.01% 525
2025
Q3 		$983 Buy
7
+1
+17% +$135 ﹤0.01% 1018
2025
Q2 		$755 Sell
6
-1
-14% -$115 ﹤0.01% 964
2025
Q1 		$775 Sell
7
-3
-30% -$380 ﹤0.01% 1092
2024
Q4 		$1.36K Buy
10
+4
+67% +$495 ﹤0.01% 888
2024
Q3 		$692 Sell
6
-3
-33% -$411 ﹤0.01% 1207
2024
Q2 		$1.24K Buy
9
+5
+125% +$686 ﹤0.01% 946
2024
Q1 		$552 Hold
4
– – ﹤0.01% 1252
2023
Q4 		$528 Buy
4
+1
+33% +$115 ﹤0.01% 1237
2023
Q3 		$338 Hold
3
– – ﹤0.01% 1343
2023
Q2 		$283 Buy
+3
New +$293 ﹤0.01% 1327
2023
Q1 		– Sell
-3
Closed -$358 – 1614
2022
Q4 		$358 Sell
3
-1
-25% -$117 ﹤0.01% 1304
2022
Q3 		$0 Buy
+4
New +$406 ﹤0.01% 1364
2022
Q1 		$0 Buy
+2
New +$169 ﹤0.01% 1124

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SJS Investment Consulting's NBIX Position: Q2 2026 in Review

SJS Investment Consulting reduced its Neurocrine Biosciences (NBIX) stake by 25% in Q2 2026, selling an estimated $12.8K and leaving 255 shares worth $43K. The position accounts for ﹤0.01% of the portfolio, ranked #520.

SJS Investment Consulting first reported a position in NBIX in Q1 2022 and has held it in 16 quarters since. The position peaked at $44.9K in Q1 2026. 780 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • SJS Investment Consulting held 255 shares of Neurocrine Biosciences worth $43K as of Q2 2026.
  • SJS Investment Consulting sold 86 Neurocrine Biosciences shares in Q2 2026, an estimated $12.8K.
  • Neurocrine Biosciences made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #520 holding.
  • SJS Investment Consulting first reported a position in Neurocrine Biosciences in Q1 2022 and has held it in 16 quarters since.
  • SJS Investment Consulting's Neurocrine Biosciences position peaked at $44.9K in Q1 2026.
  • 780 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.